Clinical value of soluble urokinase-type plasminogen activator receptor (SuPAR) as a biomarker of disease activity in Behcet’s disease
- Citation:
- Rizk, A., W. A. E. Fattah, A. Al-Shaarawy, and N. Elsaid, "Clinical value of soluble urokinase-type plasminogen activator receptor (SuPAR) as a biomarker of disease activity in Behcet’s disease", Rheumatology (Bulgaria), vol. 29, no. 4, pp. 47-52, Dec., 2021.
Abstract:
n/a
Notes:
n/a